rating

UBS Global Research downgrades Brenntag to ‘neutral’ rating By Investing.com

Investing.com — UBS Global Research has downgraded Brenntag’s (ETR:) rating to ‘neutral’ from ‘buy,’ citing concerns over the company’s inability to unlock the profit potential that was previously anticipated.  The downgrade, which marks a shift in UBS’s stance since they initiated coverage in December 2022, stems from the company’s disappointing profit…

MBX Biosciences earns Buy rating at three investment firms By Investing.com

Investing.com — Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company. Analysts at Jefferies highlighted the potential of MBX’s lead program, MBX-2109, which is currently in Phase II trials for hypoparathyroidism. They expressed confidence in the company’s…